{
    "clinical_study": {
        "@rank": "33439", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in this group will receive placebo"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group will receive Tamsulosin"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group will receive Solifenacin"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted to compare the effectiveness of alpha blocker (Tamsulosin) and\n      Anticholinergic (Solifenacin) in relieving lower urinary tract symptoms caused DJ ureteral\n      stents."
        }, 
        "brief_title": "Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ureteral Stent Related Symptoms", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient who will undergo DJ stent fixation after endoscopic procedures\n\n          1. Patient aged from 20-50 years.\n\n          2. Sexually active.\n\n          3. Indwelling time less than 3 month.\n\n          4. Unilateral DJ stent.\n\n        Exclusion Criteria:\n\n          1. Patients who had LUTS before DJ stent fixation.\n\n          2. DJ stent fixation after open surgery.\n\n          3. Indwelling time more than 3 month.\n\n          4. Bilateral DJ stent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880619", 
            "org_study_id": "Treatment of USS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group B", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group C", 
                "intervention_name": "Solifenacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholinergic Antagonists", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate", 
                "Tamsulosin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Double J", 
            "Ureteral stents", 
            "Symptoms", 
            "Alpha blockers", 
            "Anticholinergic"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mansoura", 
                    "country": "Egypt", 
                    "zip": "35516"
                }, 
                "name": "Urology and Nephrology Center"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms", 
        "overall_official": {
            "affiliation": "Urology and Nephrology Center, Mansoura University", 
            "last_name": "Ahmed R EL-Nahas, Assistant Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The Efficacy of tamsolusin and solifenacin in relieving ureteral stent symptoms will be evaluated by comparing the scores of ureteral stent symptoms quesionnaire in the studied groups", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880619"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mansoura University", 
            "investigator_full_name": "Ahmed R. EL-Nahas", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mansoura University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mansoura University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}